Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Northwestern University Eli Lilly and Company Rehabilitation Institute of Chicago |
---|---|
Information provided by: | Northwestern University |
ClinicalTrials.gov Identifier: | NCT00826228 |
Individuals with spinal cord injury sustain significant loss of bone mass in their lower extremities (20-40% or more). This study evaluates the ability of PTH and weight-bearing, two interventions that build bone, to increase bone mass in this population.
Condition | Intervention | Phase |
---|---|---|
Osteoporosis Bone Loss Spinal Cord Injury |
Drug: teriparatide Other: weight-bearing |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury |
Estimated Enrollment: | 12 |
Study Start Date: | June 2009 |
Estimated Study Completion Date: | June 2011 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
PTH/Weight-Bearing: Experimental |
Drug: teriparatide
teriparatide 20ug daily sc for 6 months
Other: weight-bearing
device assisted walking
|
This pilot project aims to evaluate PTH with weight-bearing in a group of individuals with chronic SCI and loss of bone mass in their lower extremities. A convenience sample of 12 people with SCI will be enrolled into a 6 month study assessing the effects of a weight-bearing regime plus daily PTH (Forteo 20ug sc) on BMD and bone markers. Subjects will be evaluated at 3 and 6 months after initiating treatment with measurement of bone density as well as bone markers of formation and resorption. An optional extension to 12 months will be offered to all subjects.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Lisa Maskala-Streff | 312-238-2816 | lstreff@ric.org |
United States, Illinois | |
Rehabilitation Institute of Chicago | Recruiting |
Chicago, Illinois, United States, 60611 | |
Contact: Lisa Maskala-Streff 312-238-2816 lstreff@ric.org | |
Principal Investigator: Thomas J Schnitzer, MD, PhD |
Principal Investigator: | Thomas J Schnitzer, MD, PhD | Northwestern University |
Responsible Party: | Northwestern University Feinberg School of Medicine ( Thomas J Schnitzer/Principal Investigator ) |
Study ID Numbers: | STU00003009 |
Study First Received: | January 20, 2009 |
Last Updated: | June 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00826228 History of Changes |
Health Authority: | United States: Institutional Review Board |
Spinal Cord Diseases Teriparatide Wounds and Injuries Osteoporosis Central Nervous System Diseases Disorders of Environmental Origin Bone Density Conservation Agents |
Bone Diseases, Metabolic Trauma, Nervous System Bone Diseases Hormones Body Weight Spinal Cord Injuries Musculoskeletal Diseases |
Spinal Cord Diseases Teriparatide Physiological Effects of Drugs Nervous System Diseases Wounds and Injuries Osteoporosis Central Nervous System Diseases Disorders of Environmental Origin |
Bone Diseases, Metabolic Bone Density Conservation Agents Trauma, Nervous System Bone Diseases Pharmacologic Actions Spinal Cord Injuries Musculoskeletal Diseases |